Pyrazinamide-d3

Pyrazinamide-d? is the stable isotope-labeled counterpart of Pyrazinamide. Pyrazinamide is an effective oral anti-tuberculosis antibiotic; its prodrug form is converted by pyrazinamidase (PZase) encoded by the pncA gene of Mycobacterium tuberculosis into the active pyrazinoic acid (POA), which exerts bactericidal activity against Mycobacterium tuberculosis in an acidic environment. The deuterium labeling of Pyrazinamide-d? enables its use as a quantitative tracer in pharmacokinetic and metabolism studies, helping to eliminate endogenous interference and provide more accurate exogenous data. In in vitro studies, deuterated compounds can be used to evaluate drug metabolic pathways and stability, while in animal models, Pyrazinamide-d? can be used to study drug biodistribution and clearance. The dose or concentration used in experiments typically depends on the experimental design and research objectives. It should be noted that deuteration may affect a drug’s pharmacokinetic and metabolic properties; therefore, these factors should be fully considered in study design.